Refine by
Early Disease Detection Articles & Analysis
67 news found
In diagnostics, the use of antigen rapid test kits and in vitro diagnostic hematology is accelerating early disease detection, improving treatment outcomes. Meanwhile, supragingival scaling techniques are advancing dental care, while central medical gas systems are ensuring optimal clinical environments. ...
From data to diagnostics and imaging, drug development and discovery, early intervention and predictive analytics, remote patient monitoring and robotics, AI is revolutionizing healthcare as we know it. ...
The service provides a comprehensive overview of all viral genetic material present in a sample, enabling the detection of both known and previously unknown viruses in a single assay. ...
” Lifespin is working to build new precision medicine tools based on quantitative metabolic profiles and proprietary algorithms to assist in the early detection of diseases and monitoring the efficacy of health treatments. To facilitate these services, the company has established one of the largest and most comprehensive databases of ...
Clinical laboratory testing plays an essential role in the delivery of health care. From early detection and diagnosis of disease to individualized treatment plans based on a person’s unique biology, medical care depends on accurate and timely health data. ...
Koios Medical, Inc has received 510(k) clearance from the U.S. Food and Drug Administration for Koios DS (Decision Support) Breast 2.0, a new version of its machine learning based platform that assists physicians in the classification and diagnosis of breast cancer. The software offers a proprietary alignment to BI-RADS® for any lesion analyzed and is available connected to PACS and/or ...
Villines is board-certified in internal medicine, cardiovascular diseases, cardiac computed tomography, and advanced adult echocardiography. ...
ByElucid
Proprietary microRNA signature (miRisk) may support immunotherapy treatment decisions as a blood-based complementary diagnostic Results published in Journal of Thoracic Oncology Clinical and Research Reports Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today ...
The discernible differences seem to decline in subjects with mild cognitive impairment (MCI) or overt Alzheimer’s Disease (AD), independent of age. In the healthy population, the primary differentiating features are micro hand gestures detectable on a wearable, that measured accelerometric data. ...
The discernible differences seem to decline in subjects with mild cognitive impairment (MCI) or overt Alzheimer’s Disease (AD), independent of age. In the healthy population, the primary differentiating features are micro hand gestures detectable on a wearable, that measured accelerometric data. ...
Collectively, Freeman, Datta and Henehan bring decades of experience building and growing financially successful biopharma and healthcare intelligence companies. In early April 2022, VIDA received market authorization in Japan for its VIDA Insights software, which is a complementary data-driven solution used by lung care teams at the point of care, aiding them to ...
(OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical ...
Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced the publication of a study in the journal npj Precision Oncology that describes the discovery and validation of miRisk, a first-of-its-kind microRNA (miRNA) biomarker signature that offers the prospect of a ...
The Edinburgh Royal Infirmary will evaluate suspected lung cancer patients while Groningen Medical Centre will study EMI-137 in early stage pancreatic cancer. Both centres will image EMI-137 in real time at the cellular level using endomicroscopy with Cellvizio. ...
Featured at this year’s event, Kevin Harris, President and co-Founder of CureMetrix, will present new and national research on breast cancer detection and will show how leveraging AI to stratify the risk of Coronary Heart Disease (CHD) by detecting and quantifying Breast Arterial Calcifications (BAC) can benefit imaging centers, healthcare ...
He has been instrumental in launching and scaling many industry-first technologies including the first Computer Aided Detection algorithm for the early detection of breast cancer, the first mammography analytics platform and a multi-point risk stratified breast screening scorecard. ...
n response to President Biden’s relaunch of Cancer Moonshot and his White House commitment to end cancer as we know it, healthcare technology executives for CureMetrix and CureMatch highlighted joint innovation as core to better detection and more personalized cancer treatment. “We commend President Biden’s program to end cancer as we know it, which starts with early detection ...
The research will serve as the backbone for new augmented reality tools to help at-risk individuals gain timely and accurate health insights using GN Group’s device technologies and, ultimately, to enable early detection of neurodegenerative diseases such as MCI and Alzheimer’s Disease. ...
The KBCT is expected to optimize early disease detection, diagnosis, intervention, and treatment, and will improve survival rates for millions of patients worldwide. ...
CAC is a recognized vital biomarker for detection of cardiovascular disease. Nanox.AI believes that early detection and subsequent treatment of cardiovascular disease has the potential to significantly decrease the morbidity and mortality of this highly prevalent condition. ...